Treatment options have grown increasingly complex for patients with follicular lymphoma. In this commentary, I share how I approach individualizing and sequencing therapy for patients with newly diagnosed and relapsed/refractory disease.
How are you managing patients with mantle cell lymphoma? Read this commentary for my approach.
Now that ibrutinib and zanubrutinib are both approved by the FDA in the relapsed/refractory setting for marginal zone lymphoma, where do we sequence and how do we choose between these BTK inhibitors? Read this commentary for my approach.